Japanese pharmaceutical firm Astellas has made changes to its management structure that aim to improve global product compliance and streamline global drug development.
From 1 April, all Heads of Global Development, Global Regulatory Affairs, Global Clinical Research Quality Assurance and Global Quality Assurance will report to the Chief Medical Officer. As a result, the positions of QA and RA Head of Astellas Pharma will cease to exist.
